Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

970
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
970
Neural Regulation01:37

Neural Regulation

43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Overview of Metabolism01:40

Overview of Metabolism

37.6K
Living cells constantly carry out various chemical reactions which are necessary for their proper functioning. These reactions are interlinked to one another via multiple pathways. The collection of these chemical reactions is known as metabolism.
Plant Metabolism
Sunlight, the primary source of energy in plants, is first absorbed by the chlorophyll pigments present in their leaves. Plants then use this energy to carry out photosynthesis, where water is oxidized into oxygen and carbon dioxide...
37.6K
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Extracellular matrix reprogramming by the YAP/TAZ- TGF-ß2 axis drives immune exclusion in cholangiocarcinoma models.

The Journal of clinical investigation·2026
Same author

Multimodal Phasor Analysis for Digital Pathology: Quantitative Characterization of Liver Iron Overload.

Chemical & biomedical imaging·2026
Same author

PARylation in Parkinson's disease: a bridge between Lewy body formation and neuronal cell death.

Cell death & disease·2026
Same author

KMT2A and KMT2B episignatures address diagnostic challenges associated with rare neurodevelopmental disorders.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Genetic variation in antidiabetic drug targets: associations with Parkinson's disease risk and age at onset.

NPJ Parkinson's disease·2026
Same author

Systemic Endotoxemia, Inflammatory Activation, and Lipid Dysregulation in Parkinson's Disease: Evidence from Circulating LPS-Related Biomarkers and Plasma Lipids.

International journal of molecular sciences·2026

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K

Metabolic Parkinson's disease.

Federica Invernizzi1, Lorenzo Ciocca1,2, Elena Contaldi3

  • 1Center for Liver disease, Division of Internal Medicine and Hepatology, IRCCS Ospedale San Raffaele, Milan, Italy.

Frontiers in Aging Neuroscience
|October 27, 2025
PubMed
Summary

Parkinson's disease (PD) is linked to metabolic issues like diabetes. Treatments for metabolic conditions show promise for PD, suggesting shared causes and new therapeutic avenues.

Keywords:
GLP-1/GIP RAObesityParkinson’s diseasediabetesmetabolic sybdrome

More Related Videos

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

17.3K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.9K

Related Experiment Videos

Last Updated: Jan 14, 2026

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
06:07

Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease

Published on: June 23, 2023

2.2K
The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease
15:09

The Use of Primary Human Fibroblasts for Monitoring Mitochondrial Phenotypes in the Field of Parkinson's Disease

Published on: October 3, 2012

17.3K
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

18.9K

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Pharmacology

Background:

  • Parkinson's disease (PD) involves dopaminergic neuron loss.
  • Growing evidence links PD to metabolic dysfunctions like type 2 diabetes, obesity, and metabolic syndrome.
  • Shared pathogenic mechanisms include insulin resistance, inflammation, mitochondrial dysfunction, and gut microbiota changes.

Purpose of the Study:

  • To explore the connection between metabolic disorders and Parkinson's disease.
  • To investigate potential shared etiological factors and therapeutic strategies.
  • To highlight the cross-efficacy of drugs used for both conditions.

Main Methods:

  • Review of preclinical and clinical studies on PD and metabolic disorders.
  • Analysis of shared cellular damage patterns (mitochondrial dysfunction, oxidative stress, etc.).
  • Examination of drug repurposing potential (e.g., metformin, incretin mimetics, bromocriptine).

Main Results:

  • Metabolic dysfunctions share cellular damage pathways with PD.
  • Antidiabetic drugs (metformin, incretin mimetics) show neuroprotective effects in PD.
  • Antiparkinsonian drugs (bromocriptine) improve glycemic control in diabetes.

Conclusions:

  • Shared pathogenesis between metabolic disorders and PD is hypothesized.
  • Understanding these connections can lead to novel preventive and therapeutic strategies for PD.
  • Lifestyle, dietary modifications, and repurposed drugs offer potential disease-modifying approaches.